Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention

被引：0
|
作者：
Itziar Oyagüez
Carmen Suárez
José Luis López-Sendón
José Ramón González-Juanatey
Fernando de Andrés-Nogales
Jorge Suárez
Carlos Polanco
Javier Soto
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia (PORIB),Internal Medicine Department
[2] Hospital La Princesa,Cardiology Department
[3] Hospital Universitario La Paz,Cardiology Department
[4] IdiPaz,undefined
[5] CIBER-CV,undefined
[6] Complejo Hospitalario Universitario de Compostela,undefined
[7] Bristol-Myers Squibb,undefined
[8] Pfizer,undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 497
页数：12
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF APIXABAN AGAINST CURRENT STANDARD OF CARE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN CHILE
    Vallejos, C.
    Lanas Zanetti, F.
    Castro, C.
    Bustos, L.
    VALUE IN HEALTH, 2014, 17 (03) : A117 - A117
  • [42] Cost-effectiveness of apixaban against other novel oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation patients
    Lip, G. H. Y.
    Kongnakorn, T.
    Phatak, H.
    Kuznik, A.
    Rublee, D.
    Lanitis, T.
    Liu, L.
    Iloeje, U.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 54 - 54
  • [43] Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States
    Mohan, Anjana
    Damgacioglu, Haluk
    Deshmukh, Ashish A.
    Chen, Hua
    Wanat, Matthew
    Essien, Ekere James
    Paranjpe, Rutugandha
    Fatima, Bilqees
    Abughosh, Susan
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (01) : 63 - 70
  • [44] Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients
    Lip, Gregory Y.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Liu, Larry Z.
    Lawrence, John
    Dorian, Paul
    CIRCULATION, 2014, 130
  • [45] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 709 - 721
  • [46] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Kongnakorn, Thitima
    Lanitis, Tereza
    Annemans, Lievens
    Thijs, Vincent
    Marbaix, Sophie
    CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 709 - 721
  • [47] Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
    Hallinen, Taru
    Soini, Erkki J.
    Linna, Miika
    Saarni, Samuli I.
    SPRINGERPLUS, 2016, 5
  • [48] Cost-Effectiveness of Apixaban Versus Standard Care for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece (vol 16, pg A524, 2013)
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2014, 17 (02) : 306 - 306
  • [49] COST EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS OTHER NOACS FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A487 - A487
  • [50] Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran
    Tajik, Amirmohammad
    Abbasi, Azam
    Goudarzi, Zahra
    Izadi-Moud, Azadeh
    Varmaghani, Mehdi
    CLINICAL CARDIOLOGY, 2024, 47 (06)
12345